Due To The Procurement Of The COVID-19 Vaccine, The Joint Bio Farma, Kimia Farma And Indofarma Raise Revenue Of IDR 43.4 Trillion In 2021

JAKARTA - Holding BUMN Pharmaceuticals consisting of Bio Farma, Kimia Farma and Indofarma managed to record a consolidated revenue in 2021 of IDR 43.4 trillion, driven by the procurement of the COVID-19 vaccine.

"Our revenue achievement in 2021 is IDR 43.4 trillion or 253.7 percent of the Company's Budget Performance Plan or RKAP 2021," said President Director of PT Bio Farma (Persero) as the parent of Pharmaceutical BUMN Holding Honesti Basyir in a Hearing Meeting with the Commission. VI DPR RI in Jakarta, quoted from Antara, Monday 23 May.

Honesti also added, if the income is compared to 2020, the revenue in 2021 will grow by 20.23 percent.

"This increase is mainly due to the contribution from the procurement of COVID-19 vaccines for the government of Rp. 26.81 trillion. In addition, we also get an increase in income from how we synergize with all our subsidiaries, from medical devices to medicines for handling COVID-19 , and of course the COVID-19 vaccine itself. When compared to the 2021 RKAP, there is a significant increase in its realization," he explained.

From the EBITDA posture, Pharmaceutical Holding BUMN also experienced a very significant increase compared to 2020 where Pharmaceutical Holding EBITDA grew by 206.3 percent. Pharmaceutical Holding's EBITDA in 2021 was recorded at Rp4.02 trillion.

"Then also for the profit and loss posture in 2021, we consolidated a net profit of IDR 1.93 trillion or reached 186.9 percent of the 2021 RKAP," said the Director of Bio Farma.

When compared to 2020, the consolidated net profit of the Pharmaceutical BUMN Holding in 2021 grew by 567.8 percent.

The increase in net profit is also of course due to the impact of the COVID-19 pandemic handling process, both assigned and directly carried out in the regular sector.